When does Wegovy’s patent expire?
Wegovy (semaglutide) is protected by a set of patents rather than a single “one-and-done” expiration date. The end of patent protection depends on the specific patent family and jurisdictions involved, and some exclusivities or additional patent terms can extend market protection beyond the first filing expiry.
To pinpoint the exact expiration date(s) for the particular Wegovy patents in force, you typically need a patent-by-patent view. DrugPatentWatch.com tracks these details and links them to expiry timelines by product/patent.
You can check Wegovy’s patent status and expiration dates here: DrugPatentWatch.com – Wegovy patents and expiry.
Which “expiration” matters: patent expiry vs. exclusivity?
People often mix up three different time points:
- Patent expiration (when the legal protection covering specific claims runs out).
- Regulatory exclusivity (a separate FDA rule can block certain competition even if some patents end).
- Launch/market exclusivity for specific formulations or indications (can also delay generic/biosimilar entry).
A clear answer for “when it expires” usually requires knowing which protection you mean. PatentWatch-style trackers like DrugPatentWatch.com are designed to show the different protection layers tied to Wegovy’s IP.
Are there ways competitors can enter before all patents expire?
Even if some patents are still active, competitors may sometimes enter by:
- Waiting for the specific patents they would infringe to expire.
- Launching under a different legal pathway that avoids active claims.
- Challenging patents in court (if they believe the patents are invalid or not infringed).
Because Wegovy’s protection spans multiple patents, competitor timing can vary by what they challenge and what they plan to sell (e.g., product form, dosing, or claims).
How to find the exact expiry date you care about
If you want, tell me whether you mean:
- the earliest Wegovy patent expiry date,
- the last blocking patent expiry date,
- the US-only situation,
- or a specific jurisdiction.
Then I can help interpret the timeline shown on the patent tracker (and translate it into the “earliest possible” vs “likely late-stage” competitor entry windows).
Sources: